Multiple myeloma therapeutics industry is projected to witness a CAGR of 6.4% during the period 2024-2032. This growth can be ...

"Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial" was originally created and published by Clinical ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

More than 200 people were reported rescued from floodwaters in North Carolina following Helene’s torrential rains with more ...

Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes back.

As part of his upcoming tell-all memoir 'Unleashed' Boris Johnson recalled his final meeting with the monarch, stating he had ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers. Read why I now taper my rating for CRBU ...

In his memoir, Unleashed, Boris Johnson also revealed that the Queen had told him: "There's no point in bitterness" ...

In his tell-all memoir, the disgraced Tory and former Prime Minister also appeared to break convention by revealing advice given to him by the monarch just two days before she died ...